Table 3. Characteristics of patients with squamous cell lung cancer with ALK rearrangement.
| Squamous cell carcinoma (including two AdSq cases) |
Adenocarcinoma | |
|---|---|---|
| Number of patients | 5a | 25 |
| Year (mean ± SD [range]) | 54.8 ± 12.8 [36–65] | 59.1 ± 13.1 [38–83] |
| Male/female | 3/2 | 16/9 |
| % male | 60.0% | 64.0% |
| Smoking rate (%) | 4/5 (80.0) | 17/25 (68.0) |
| I/II/III/IV | 0/0/1/4 | 3/1/5/16b |
| Treatment history Number of patients |
||
| First ALK inhibitor C/A/Ce | 5/0/0 | 8/6/0 |
| Second ALK inhibitor C/A/Ce | 3/0/0 | 0/6/0 |
| Third ALK inhibitor C/A/Ce | 0/0/2 | 0/0/0 |
| Previous chemo and chemo + rad | ||
| Number of patients | 5 | 7 |
| ALK mutation detection | ||
| Number of patients (%) | ||
| IHC | 3 (60.0) | 21 (84.0) |
| FISH | 5 (100.0) | 24 (96.0)c |
A, alectinib; C, crizotinib; Ce: ceritinib; chemo, chemotherapy; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; rad: radiation therapy.
aTwo patients were added from Urayasu Hospital for statistical analysis.
bTwo patients underwent an operation; four relapsed after operation.
cOne case was indeterminate.